Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000920576 | SCV001065947 | likely benign | Severe X-linked myotubular myopathy | 2024-08-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001595056 | SCV001829607 | uncertain significance | not provided | 2020-06-26 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; In-silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown. |
Ambry Genetics | RCV002540970 | SCV003531492 | uncertain significance | Inborn genetic diseases | 2022-07-08 | criteria provided, single submitter | clinical testing | The c.1376A>G (p.N459S) alteration is located in exon 13 (coding exon 12) of the MTM1 gene. This alteration results from a A to G substitution at nucleotide position 1376, causing the asparagine (N) at amino acid position 459 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000920576 | SCV001462909 | likely benign | Severe X-linked myotubular myopathy | 2020-09-16 | no assertion criteria provided | clinical testing |